M.E. Fibro Study: Genetic Proof of Biological Cause
Groundbreaking Genetic Study of ME/CFS Fuels Calls for Improved Care in Northern Ireland
Table of Contents
The lives of people living with Myalgic Encephalomyelitis (M.E.), also known as Chronic Fatigue Syndrome (CFS), in northern Ireland could be dramatically improved following the discovery of significant genetic differences between M.E. patients and the general population. The findings, from the groundbreaking DecodeME study, are bolstering calls for increased investment in specialist services, research, and education within the region.
Rising M.E. Prevalence and a Critical lack of Support
The number of individuals diagnosed with M.E. in Northern Ireland has risen sharply in recent years, now estimated at 12,500 - a significant increase from the 7,500 reported previously. Despite this growing need, the region remains severely underserved, with no clinical lead, specialist services, or commissioned care pathways currently available for M.E. patients.”We urge the Department of Health and our elected representatives to respond to this evidence and finally deliver the services people with M.E. desperately need,” advocates state.
This lack of support leaves many patients struggling with minimal or no assistance, impacting their quality of life and ability to manage a debilitating chronic condition. hope 4 ME & Fibro NI has been at the forefront of raising awareness, including a recent World M.E. Day event at Stormont attended by Health Minister Mike Nesbitt and a cross-party group of MLAs.
DecodeME: A “game-Changer” in Understanding M.E.
The DecodeME study, funded by the Medical Research council and the National Institute for Health and Care Research (NIHR), represents a pivotal moment in M.E. research. Professor Tom Trinnick OBE, former Clinical Director of Laboratory Medicine at South Eastern Trust and medical advisor for Hope 4 ME & Fibro, welcomed the news, stating: “The groundbreaking DecodeME study of the genetics of patients with ME/CFS shows significant genetic differences in patient DNA compared to the general population.”
These genetic differences offer vital biological clues into the cause and progression of M.E., particularly concerning immune response and chronic pain.Joan McParland of Hope 4 ME & Fibro NI described the discovery as a “game-changer,” adding, “This must put an end to outdated misconceptions and lead to proper medical education, specialist clinics, and funded research, including here in Northern Ireland.”
What the Genetic Findings Mean for Future Treatment
The DecodeME results are expected to shape future research and treatment strategies for M.E. By identifying specific genetic markers associated with the condition, scientists can begin to develop targeted therapies and diagnostic tools.Further analysis is ongoing to fully understand the implications of these findings.
The study reinforces the urgent need for:
immediate investment in clinical care: Providing accessible and extensive care for M.E. patients.
Professional education: Equipping healthcare professionals with the knowledge and skills to accurately diagnose and manage M.E.
Expanded research: Continuing to investigate the biological mechanisms underlying M.E. to develop effective treatments.
support and resources for People with M.E. in Northern ireland
Hope 4 ME & Fibro Northern Ireland plays a crucial role in supporting individuals and families affected by M.E. and fibromyalgia. They offer:
Monthly Zoom support meetings: Providing a safe and supportive space for individuals to connect and share experiences.
Annual conferences: Featuring leading experts in the field, offering valuable insights and data.
A vital community lifeline: Connecting people with resources and support networks.
To learn more about the work of Hope 4 ME & Fibro Northern Ireland, visit hope4mefibro.org.
Further information about the DecodeME findings can be found at decodeme.org.uk/initial-dna-results.